Amneal receives 505(b)(2) nda approval from fda for pemrydi rtu®, a ready-to-use oncology injectable

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal” or the “company”) today announced the 505(b)(2) new drug application (nda) approval from the u.s. food and drug administration (“fda”) for pemrydi rtu®. this product is the first and only ready-to-use presentation of pemetrexed for injection and does not require reconstitution, dilution, or refrigeration. this injectable will be available in three vial sizes: 100mg/10ml; 500 mg/50ml; and 1,000mg/100ml. the c.
AMRX Ratings Summary
AMRX Quant Ranking